Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (vol 8, e000891, 2020)

被引:0
|
作者
Motzer, R. J.
Escudier, B.
McDermott, D. F.
机构
关键词
D O I
10.1136/jitc-2020-000891corr1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页数:1
相关论文
共 50 条
  • [41] Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
    Albiges, L.
    Tannir, N.
    Burotto, M.
    McDermott, D. F.
    Plimack, E. R.
    Barthelemy, P.
    Porta, C. G.
    Powles, T. B.
    Donskov, F.
    George, S.
    Kollmannsberger, C.
    Gurney, H.
    Grimm, M-O.
    Tomita, Y.
    Castellano Gauna, D.
    Rini, B. I.
    Choueiri, T. K.
    Saggi, S. S.
    McHenry, M. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S559 - S560
  • [42] Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.
    Powles, Thomas
    Choueiri, Toni K.
    Burotto, Mauricio
    Escudier, Bernard
    Bourlon, Maria Teresa
    Shah, Amishi Yogesh
    Suarez, Cristina
    Hamzaj, Alketa
    Porta, Camillo
    Hocking, Christopher
    Kessler, Elizabeth R.
    Gurney, Howard
    Tomita, Yoshihiko
    Bedke, Jens
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Apolo, Andrea B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [43] Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
    Ascierto, Paolo A.
    Long, Georgina V.
    Robert, Caroline
    Brady, Benjamin
    Dutriaux, Caroline
    Di Giacomo, Anna Maria
    Mortier, Laurent
    Hassel, Jessica C.
    Rutkowski, Piotr
    McNeil, Catriona
    Kalinka-Warzocha, Ewa
    Savage, Kerry J.
    Hernberg, Micaela M.
    Lebbe, Celeste
    Charles, Julie
    Mihalcioiu, Catalin
    Chiarion-Sileni, Vanna
    Mauch, Cornelia
    Cognetti, Francesco
    Ny, Lars
    Arance, Ana
    Svane, Inge Marie
    Schadendorf, Dirk
    Gogas, Helen
    Saci, Abdel
    Jiang, Joel
    Rizzo, Jasmine
    Atkinson, Victoria
    JAMA ONCOLOGY, 2019, 5 (02) : 187 - 194
  • [44] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
    Motzer, R. J.
    Powles, T.
    Burotto, M.
    LANCET ONCOLOGY, 2022, 23 (07): : E319 - E319
  • [45] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
    Vergote, I
    Gonzalez-Martin, A.
    Lorusso, D.
    LANCET ONCOLOGY, 2022, 23 (09): : E404 - E404
  • [46] Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
    Powles, Thomas
    Plimack, Elizabeth R.
    Soulieres, Denis
    Waddell, Tom
    Stus, Viktor
    Gafanov, Rustem
    Nosov, Dmitry
    Pouliot, Frederic
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Azevedo, Sergio J.
    Borchiellini, Delphine
    McDermott, Raymond S.
    Bedke, Jens
    Tamada, Satoshi
    Yin, Lina
    Chen, Mei
    Molife, L. Rhoda
    Atkins, Michael B.
    Rini, Brian, I
    LANCET ONCOLOGY, 2020, 21 (12): : 1563 - 1573
  • [47] Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
    Cella, David
    Motzer, Robert J.
    Suarez, Cristina
    Blum, Steven, I
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel F.
    Simsek, Burcin
    Zhang, Joshua
    Ivanescu, Cristina
    Apolo, Andrea B.
    Choueiri, Toni K.
    LANCET ONCOLOGY, 2022, 23 (02): : 292 - 303
  • [48] Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial (vol 6, pg 1247, 2020)
    Choueiri, T. K.
    Heng, D. Y. C.
    Lee, J. L.
    JAMA ONCOLOGY, 2020, 6 (09) : 1473 - 1473
  • [49] Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomized, phase 3 study
    Motzer, R.
    Porta, C.
    Alekseev, B.
    Rha, S. Y.
    Choueiri, T. K.
    Mendez-Vidal, M. J.
    Hong, S. H.
    Kapoor, A.
    Goh, J. C.
    Eto, M.
    Bennett, L.
    Wang, J.
    Pan, J. J.
    Saretsky, T. L.
    Perini, R. F.
    He, C. S.
    Mody, K.
    Cella, D.
    ONKOUROLOGIYA, 2022, 18 (02): : 39 - 57
  • [50] Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial (vol 5, pg 187, 2018)
    Ascierto, P. A.
    Long, G., V
    Robert, C.
    JAMA ONCOLOGY, 2019, 5 (02) : 271 - 271